At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 9 target
Drug / intervention
Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cellscombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-NKT in the Treatment of Relapsed or Metastatic Advanced Renal Cell Carcinoma.
In Brief
A Phase 1 clinical trial evaluating Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells for Renal Cell Carcinoma. Targeting 9 participants across 1 site.
Detailed Summary
This is a phase I, open-label, single-arm study conducted to evaluate the safety, tolerability, PK, and preliminary efficacy of CGC729 with Relapsed or Metastatic advanced renal cell carcinoma. Condition or disease:Renal Cell Carcinoma Intervention/treatment: Biological: CD70 CAR-NKT cells Phase 1
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
202420252026
Enrollment StartJul 2023
First PostedDec 2023
Primary CompletionJan 2025
TodayJul 2026
First PostedDec 27, 2023
Enrollment StartJul 17, 2023
Primary CompletionJan 28, 2025
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 2.5 years ago
Interventions
Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cellscombination
Biological: CD70 CAR-NKT cells. Drug: Cyclophosphamide. Drug: Fludarabine.